(Reuters) – Eli Lilly (NYSE:) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
The company has received the Hong Kong government approval to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
Want to make your savings work harder for you? Here’s how to maximize the interest rate on your savings account....
A sword in World of Warcraft once sold for over $16,000.A rare Fortnite skin can resell for hundreds of dollars.And...
The era of manual spreadsheets and phone calls to manage customer returns and excess inventory is rapidly fading. In its...
Americans are carrying over $1 trillion in credit card debt, according to the Federal Reserve. With average annual percentage rates...
For many college students, getting a first credit card is a major step toward financial independence. Used wisely, student credit...
If you ask most people what it takes to build wealth, you’ll probably hear some version of: “Get a good...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
